Resmed Inc banner

Resmed Inc
ASX:RMD

Watchlist Manager
Resmed Inc Logo
Resmed Inc
ASX:RMD
Watchlist
Price: 28.7 AUD -3.63%
Market Cap: AU$28B

EV/GP

9.2
Current
24%
Cheaper
vs 3-y average of 12.1

Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.

EV/GP
9.2
=
Enterprise Value
AU$35.7B
/
Gross Profit
$3.3B

Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.

EV/GP
9.2
=
Enterprise Value
AU$35.7B
/
Gross Profit
$3.3B

Valuation Scenarios

Resmed Inc is trading below its 3-year average

If EV/GP returns to its 3-Year Average (12.1), the stock would be worth AU$37.85 (32% upside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-44%
Maximum Upside
+52%
Average Upside
3%
Scenario EV/GP Value Implied Price Upside/Downside
Current Multiple 9.2 AU$28.7
0%
3-Year Average 12.1 AU$37.85
+32%
5-Year Average 13.9 AU$43.72
+52%
Industry Average 5.2 AU$16.14
-44%
Country Average 6.5 AU$20.41
-29%

Forward EV/GP
Today’s price vs future gross profit

Not enough data available to calculate forward EV/GP

Peer Comparison

All Multiples
EV/GP
P/E
All Countries
Close

Market Distribution

In line with most companies in the United States of America
Percentile
59th
Based on 9 428 companies
59th percentile
8.1
Low
0 — 4.2
Typical Range
4.2 — 10.6
High
10.6 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 4.2
Median 6.5
70th Percentile 10.6
Max 1 764 211.7

Resmed Inc
Glance View

ResMed Inc. has built its legacy on a profound, technological commitment to improving the lives of millions worldwide who suffer from sleep-related breathing disorders. Emerging as a beacon in the field of medical device innovation, the company is renowned for its focus on designing and manufacturing equipment to treat sleep apnea, a condition where breathing repeatedly stops and starts during sleep. Their product line, which includes continuous positive airway pressure (CPAP) devices, ventilators, and masks, caters to hospitals, home healthcare settings, and individuals. By addressing this critical health issue, ResMed doesn't just deliver therapeutic equipment; it offers a lifeline to those battling sleep health challenges, ensuring that restful nights translate into healthier days. The company's revenue model pivots around an integrated approach combining hardware sales, software solutions, and cloud-connected offerings. Through its software, ResMed analyzes vast pools of patient data, enabling healthcare providers to tailor and improve therapeutic protocols, thus driving the efficacy of treatment plans. The increasing turn towards digital health technologies has also opened new avenues, with the company's cloud platforms and analytics delivering value-added insights to care providers. This convergence of medical equipment and digital technology provides ResMed not just a steady growth trajectory, but also positions it at the forefront of a healthcare evolution, turning data-driven intelligence into actionable health solutions.

RMD Intrinsic Value
33.65 AUD
Undervaluation 15%
Intrinsic Value
Price AU$28.7
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett